Stock Buzzer: Can Ionis Pharmaceuticals Inc’s Tomorrow be Different? The Stock Declines Again

Stock Buzzer: Can Ionis Pharmaceuticals Inc's Tomorrow be Different? The Stock Declines Again

The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) is a huge mover today! About 3.28M shares traded hands or 56.94% up from the average. Ionis Pharmaceuticals Inc (NASDAQ:IONS) has declined 30.97% since April 6, 2016 and is downtrending. It has underperformed by 32.93% the S&P500.
The move comes after 6 months negative chart setup for the $4.47 billion company. It was reported on Nov, 8 by Barchart.com. We have $29.69 PT which if reached, will make NASDAQ:IONS worth $223.50M less.

Analysts await Ionis Pharmaceuticals Inc (NASDAQ:IONS) to report earnings on November, 14. They expect $-0.01 EPS, up 96.67% or $0.29 from last year’s $-0.3 per share. After $-0.47 actual EPS reported by Ionis Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -97.87% EPS growth.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Ratings Coverage

Out of 2 analysts covering Ionis Pharmaceuticals Inc (NASDAQ:IONS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Ionis Pharmaceuticals Inc has been the topic of 3 analyst reports since February 22, 2016 according to StockzIntelligence Inc. As per Friday, May 27, the company rating was downgraded by BMO Capital Markets. The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) earned “Buy” rating by Needham on Friday, May 27.

According to Zacks Investment Research, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.”

More notable recent Ionis Pharmaceuticals Inc (NASDAQ:IONS) news were published by: Fool.com which released: “Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today” on November 07, 2016, also Fool.com with their article: “Better Buy: Ionis Pharmaceuticals, Inc. vs. Celgene” published on October 17, 2016, Prnewswire.com published: “Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in …” on November 01, 2016. More interesting news about Ionis Pharmaceuticals Inc (NASDAQ:IONS) were released by: Prnewswire.com and their article: “Webcast Alert: Ionis Pharmaceuticals’ Third Quarter 2016 Financial Results …” published on October 26, 2016 as well as Fool.com‘s news article titled: “5 Reasons Ionis Pharmaceuticals Is a Top Stock to Buy Now” with publication date: October 28, 2016.

IONS Company Profile

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., incorporated on March 25, 1991, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Firm operates through two divisions: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the activities of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Firm is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. The Company’s Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment